| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Fin. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry. vol 29. issue 4. 1996-12-17. PMID:8858716. |
administration of medications which affect brain dopamine and serotonin levels are occasionally associated with neurotoxic behavioral and autonomic syndromes, variously described as the neuroleptic malignant (nms) and the toxic serotonin (tss) syndromes. |
1996-12-17 |
2023-08-12 |
Not clear |
| M Fin. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry. vol 29. issue 4. 1996-12-17. PMID:8858716. |
we describe a case of neurotoxic syndrome with characteristics indistinguishable from nms in which the offending agents are those which affect the serotonin and not the dopamine systems. |
1996-12-17 |
2023-08-12 |
Not clear |
| H Miyaoka, K Kamijim. Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? International clinical psychopharmacology. vol 10. issue 4. 1996-09-26. PMID:8748050. |
this patient could have been diagnosed as having either neuroleptic malignant syndrome (nms) or serotonin syndrome (ss). |
1996-09-26 |
2023-08-12 |
Not clear |
| K Nisijima, T Ishigur. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. Journal of psychiatric research. vol 29. issue 3. 1995-12-06. PMID:7473299. |
therefore, a relationship between the development of nms and disturbances of serotonin metabolism remains unclear. |
1995-12-06 |
2023-08-12 |
Not clear |
| G J Wang, N D Volkow, J Logan, J S Fowler, D Schlyer, R R MacGregor, R J Hitzemann, R C Gur, A P Wol. Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life sciences. vol 56. issue 14. 1995-11-27. PMID:7475891. |
we assessed the relation between serotonin 5-ht2 receptor availability and aging and compared it with that for dopamine d2 receptors on 19 healthy male volunteers (age range, 21-49 years) using positron emission tomography (pet) and f-18 n-methylspiperone (nms). |
1995-11-27 |
2023-08-12 |
human |
| V Y Totten, E Hirschenstein, P He. Neuroleptic malignant syndrome presenting without initial fever: a case report. The Journal of emergency medicine. vol 12. issue 1. 1994-05-26. PMID:8163804. |
nms shares features with malignant hyperthermia, serotonin syndrome, lethal catatonia, and heat stroke. |
1994-05-26 |
2023-08-12 |
Not clear |
| M Halman, D S Goldbloo. Fluoxetine and neuroleptic malignant syndrome. Biological psychiatry. vol 28. issue 6. 1990-12-07. PMID:2223920. |
on reviewing the literature on the pathogenesis of nms, the authors hypothesize a facilitative role of the neurotransmitter serotonin (5-ht) in conjunction with central dopaminergic blockade in the precipitation of nms. |
1990-12-07 |
2023-08-11 |
Not clear |
| K Nisijima, T Ishigur. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biological psychiatry. vol 27. issue 3. 1990-03-28. PMID:1689186. |
the levels of 5-hiaa in patients with active nms and after recovery were also significantly lower than those in normal control group, suggesting a relationship between the development of nms and a disturbance of serotonin metabolism. |
1990-03-28 |
2023-08-11 |
human |
| K Nishijima, T Ishigur. [Clinical course and CSF monoamine metabolism in neuroleptic malignant syndrome--a study of nine typical cases and five mild cases]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 91. issue 6. 1989-11-30. PMID:2479043. |
the levels of 5-hiaa in the active phase of typical nms and after recovery were also significantly lower than those in normal control group, suggesting a relationship between the development of nms and a disturbance of serotonin metabolism. |
1989-11-30 |
2023-08-11 |
human |